References
- Winchester DP, Sylvester J, Maker ML. Risks and benefits of mass screening for colorectal neoplasia with the stool guaiac test. Cancer 1983: 33(6): 333–43
- Fink DJ. Facts about colorectal cancer detection. Cancer 1983: 33(6): 366–7
- Eiseman B, Steele G, eds. Follow-up of the cancer patient. New York: Thieme-Stratton, 1982
- Graffner H, Hultberg B, Johansson B, et al. Detection of recurrent cancer of the colon and rectum. J Surg Oncol 1985: 28(2): 156–9
- Sugarfoaker PH, Zamcheck N, Moore FD. Assessment of serial carcinoembryonic antigen (CEA) assays in postoperative detection of recurrent colorectal cancer. Cancer 1976: 38(6): 2310–5
- Adson MA, van Heerden JA, Adson MH. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984: 119: 647–51
- Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following “curative surgery” for adenocarcinoma of the rectum: clinicopathologic correlation and implications for adjuvant therapy. Cancer 1974: 34(4): 1278–92
- Gilbert JM. Adjuvant chemotherapy of large bowel cancer. Cancer Treat Rev 1982: 9(3): 195–228
- Ansfleld F, Klotz J, Nealon T, et al. A phase m study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report. Cancer 1977: 39(1): 34–40
- Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer: results of a prospectively randomized trial. N Engl J Med 1984: 310(12): 737–43
- Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988: 80(1): 30–6
- Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988: 80(1): 21–9
- Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985: 312(23): 1465–72
- Attiyeh FF, Stearns MW Jr. Second-look laparotomy based on CEA elevations In colorectal cancer. Cancer 1981: 47(9): 2119–25
- Carter SK. Large-bowel cancer: the current status of treatment. (Editorial) J Natl Cancer Inst 1976: 56(1): 3–10
- Budd GT, Fleming TR, Bukowski RM, et al. 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group study. J Clin Oncol 1987: 5(2): 272–7
- Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988: 6(3): 469–75
- Herrmann R, Spehn J, Beyer JH, et al. Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer. J Clin Oncol 1984: 2(6): 591–4
- Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987: 5(10): 1559–65
- Hohn D, Stagg R, Friedman M, et al. The NCOG randomized trial of intravenous vs hepatic arterial (IA) FUDR for colorectal cancer metastatic to the liver. (Abstr) Proc Am Soc Clin Oncol 1987: 6: 85
- Ensmlnger WD. Intraarterial chemotherapy for the treatment of hepatic metastases. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 2d ed, update No. 5. Philadelphia: JB Lippincott, 1987: 1–11
- Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987: 107(4): 459–65